|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.01|
Belgravia first invested in Tartisan in March 2018 and to date has invested over $800,000. The return that the Tartisan Board gave us on our investment has wiped out approximately half our initial share value. We know that other shareholders have suffered far worse losses as a result of the current Board’s incompetence. The Board members of Belgravia became so concerned with the speed and depth of Tartisan’s plummeting share price that they decided to diligently investigate the cause. Our first step was to use every shareholders’ legal right to examine the corporate minute book, however Belgravia’s representative was repeatedly refused access to the minute books. We then conducted a search of Tartisan’s public filings on SEDAR and the public records alarmed us.
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (BLGVF) (“Belgravia” or the “Company”) is pleased to provide a corporate update in respect of corporate activities. Belgravia holds seventeen investments in thirteen public and four private corporations. Updates are provided directly below for five core holdings.
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (BLGVF) (“Belgravia” or the “Company”) today announced that its subsidiary, Belgravia Dermatology Inc. (“Belgravia Dermatology”) has completed the selection of initial drug targets and biological markers for its pre-clinical work in cannabinoid based dermatological treatments for unmet medical needs. The Company’s indications of interest include acne, atopic dermatitis, and psoriasis. The initial focus of product development is acne.
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2018) - Mehdi Azodi, President & CEO of Belgravia Capital Inc. talks about the company's rapid growth phase that will benefit investors.If you cannot view the video above, please visit:http://www.b-tv.com/belgravia-ceo-clip-90sec/Belgravia Capital Inc.: (CSE: BLGV)Belgravia Capital International Inc. is focused on its three core business divisions: Incubation, Investments and also Royalties. Belgravia will also develop new companies with a focus on the legal medical cannabis industry. The incubation ...
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (BLGVF) (“Belgravia Capital”, “Belgravia”, or the “Company”) is pleased to announce that it has acquired 10.03% of the outstanding common shares of R&D Pharma Corp. (“RDP”). RDP is a Canadian corporation developing a vertically integrated medicinal cannabis business in Jamaica. Belgravia has acquired four million (4 million) common shares of RDP at a price of twenty-five (25) cents per share. Belgravia has the right to appoint an independent director to the Board of RDP. Mr. Kevin Strong, the Chief Financial Officer (“CFO”) of Belgravia, has been appointed CFO of RDP. The funding of the acquisition was by way of Canadian $500,000 (five-hundred thousand dollars) and 5,000,000 (five million) common shares of Belgravia.
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2017) - Belgravia Capital International (CSE: BLGV) (OTCQB: BLGVF) is the latest new listing on the Canadian Securities Exchange, trading under the symbol "BLGV", having previously traded as IC Potash on the Toronto Stock Exchange under the symbol "ICP". InvestmentPitch Media has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter ...